• 대한방사선기술학회지:방사선기술과학
• /
• 제39권4호
• /
• pp.607-614
• /
• 2016

토모를 이용한 회전 방사선치료 시 2차원적인 선량분포 평가 대신 3차원적 선량분포 평가의 필요성에 관하여 연구하였다. 토모 치료 부위의 정확한 선량분포를 측정하기 위하여 RANDO phantom을 이용하였으며, 평가 대조군으로 gafchromic EBT2 필름의 선량분포와 3차원 체적팬텀인 ArcCHECK phantom을 이용하여 3차원적인 선량분포를 gamma correction(3%/3 mm, 2%/2 mm)으로 평가하였다. 팬텀에 대한 치료 영역은 각각 0.5, 1, 1.5, 2, 2.5, 3 cm로 설정하였으며, 처방선량을 1,200 cGy로 하여 5회씩 선량을 조사하였다. Gafchromic EBT2 필름을 이용한 절대선량 측정 시 평균오차는 $0.76{\pm}0.59%$이었으며, ArcCHECK phantom을 이용한 절대선량 측정 시 평균오차는 $1.37{\pm}0.76%$로 나타났다. 선량분포의 평가에서 gafchromic EBT2 필름인 경우 gamma correction(3%/3 mm)은 평균 $97.72{\pm}0.02%$, ArcCHECK phantom인 경우 평균 $99.26{\pm}0.01%$로 측정되었다. 또한 gafchro mic EBT2 필름에서 gamma correction(2%/2 mm)의 평균은 $94.21{\pm}0.02%$이며, ArcCHECK phantom에서는 평균은 $93.02{\pm}0.01%$로 측정되었다. 토모치료를 이용한 환자 DQA에서 3차원 체적팬텀인 ArcCHECK phantom을 이용한 선량분포 평가가 cheese phantom을 이용한 선량분포 평가에 비하여 치료영역 주변부에 대한 정확한 측정과 실시간 평가가 가능하므로 환자의 치료가 보다 더 정확하고 빨리 이루어질 수 있을 것으로 사료된다.

• 대한방사선치료학회지
• /
• 제29권1호
• /
• pp.37-48
• /
• 2017

목 적: 방사선치료의 가장 기본적인 조건은 정상조직의 불필요한 피폭을 방지하는 것이다. 유방암의 경우는 폐와 심장에 조사되는 선량이 중요하게 평가되는 인자이다. 따라서 유방암 방사선치료 자세에 따른 정상조직에 조사되는 선량을 비교하고 그 연관성을 상관관계 분석을 통하여 결과를 확인하여 보다 효과적인 유방암 방사선 치료방법을 모색하고자 한다. 대상 및 방법: 본원을 내원한 좌측 유방암 환자 30명을 대상으로 Supine, Prone Position에서 CT image를 획득하였다. Eclipse Treatment Planning System(Version 11, USA)을 이용하여 전산화치료계획을 수립하였다. DVH(Dose Volume Histogram)을 통해 Position 별로 정상조직에 조사된 선량을 비교하였다. 그 결과를 바탕으로 SPSS(Version 18)을 이용하여 각 정상조직의 선량인자를 통계분석하고 항목 간 상관관계 분석 및 독립표본 t-test를 통하여 그 연관성을 알아보았다. 그리고 MIRADA RTx(Version Advanced 1.6, UK)를 이용하여 HI(Homogeneity Index)와 CI(Conformity Index)를 Supine, Prone Position에서 값을 구하고 비교하였다. 결 과: 유방암의 전산화치료계획의 결과 폐의 경우는 Supine Position에서 V20은 $16.5{\pm}2.6%$, V30은 $13.8{\pm}2.2%$, Mean dose는 $779.1{\pm}135.9cGy$(Absolute value)를 보였다. Prone Position은 위 순서대로 $3.1{\pm}2.2%$, $1.8{\pm}1.7%$, $241.4{\pm}138.3cGy$를 보였다. Prone Position이 전반적으로 낮은 선량을 나타내었고 평균선량 537.7 cGy가 더 적게 폐에 조사되었다. 심장의 경우에는 Supine, Prone 순서대로 V30은 $8.1{\pm}2.6%$, $5.1{\pm}2.5%$, Mean dose는 $594.9{\pm}225.3cGy$, $408{\pm}183.6cGy$를 보였다. Prone Position에서 평균선량 182.6 cGy가 더 적게 조사된다는 것을 확인하였다. 통계분석 결과 신뢰도 분석지표인 Cronbach's Alpha value는 0.563이였고 변수간의 상관관계분석 결과 치료자세와 폐의 선량평가인자는 대략 0.89 이상으로 그 상관관계가 높았다. 반면 심장의 경우는 V30은 0.488, Mean dose는 0.418로 상관관계가 다소 적었다. 마지막으로 독립표본 t-test 결과 치료자세와 폐, 심장의 선량평가인자가 신뢰수준 99 %에서 모두 유의하게 나타났다($p-value{\leq}0.05$). 결 론: 현재 방사선치료는 최첨단 선형가속기와 다양화된 전산화치료계획 기술이 개발되고 있다. 이 발전의 기본전제 조건은 PTV(Planning Target Volume) 주위의 정상조직 보호라고 생각한다. 물론 유방암 환자를 Prone Position에서 치료하면 Set-up의 재현성 문제와 다소 많은 시간이 소요되지만 이 실험결과에서 보듯이 Prone Position에서 폐와 심장에 들어가는 선량을 줄일 수 있으며 그 연관관계도 의미가 있다는 것을 확인하였다. 결론적으로 Prone Position에서 충분한 치료시간을 확보하고 정확한 치료부위 확인이 이루어진다면 환자에게 보다 좋은 방사선치료를 제공할 수 있다고 생각된다.

• 대한한의학방제학회지
• /
• 제10권1호
• /
• pp.131-142
• /
• 2002

The effect of Banhasasim-tang extracts on the cardiac toxicity and general symptom induced by Doxorubicin administration(Three injection protocol) were monitored using male ICR mice. The changes of body weight, clinical signs, necropsy findings and organ weights of heart were observed. The results were as followed. 1. Decrease of body weight after Doxorubicin treatment were dose-dependently inhibited by Banhasasim-tang extracts. 2. The degrees of anorexia, ataxia and dehydration that were observed in Doxorubicin treatment group were dose-dependently inhibited by Banhasasim-tang extracts. 3. Increase of absolute and relative heart weight observed in Doxorubicin treatment group were dose-dependently inhibited by Banhasasim-tang extracts. In addition. the degrees of heart congestion and enlargement were significantly and dose-dependently decreased after Banhasasim-tang extracts dosing groups compared to that of Doxorubicin treatment group. In conclusion, the toxicity of Doxorubicin treatment(decrease of body weights, clinical signs such as anorexia, ataxia and dehydration, changes of organ weights of heart) was inhibited and/or prevented by Banhasasim-tang extracts. According to these results. it is considered that Banhasasim-tang has some preventive effect against to toxicity induced by Doxorubicin.

• Biomolecules & Therapeutics
• /
• 제11권3호
• /
• pp.163-168
• /
• 2003

Pharmacokinetics of eupatilin (an active components of $Stillen^{\circledR}$, a new antigastritic agent) were investigated after both intravenous and oral administration at a dose of 30mg/kg to rats. After intravenous administration, the plasma concentrations of unchanged eupatilin declined rapidly with a mean terminal half-life of 0.101 h. Eupatilin was eliminated fast in rats; the total body clearance was 121 mL/min/kg. Eupatilin was mainly metabolized in rats; the percentage of intravenous dose of eupatilin excreted in 24 h urine and feces as unchanged eupatilin was only 2.5 and 0.919％, respectively. Eupatilin was mainly metabolized to form its glucuronide conjugate; after intravenous administration, 15.9 and 51.7％ of intravenous dose was excreted in 24 h urine and feces, respectively, as eupatilin plus its glucuronide. After oral administration, the absolute bioavailability was only 3.86％ based on $AUC_{0-24h}$ of eupatilin plus its glucuronide. Approximately 68.5％ of oral dose was not absorbed from the entire gastrointestinal tract. Therefore, it could be concluded that the superior effect of eupatilin in experimental animal models of gastric ulcer and inflammatory bowel disease after oral administration could be due to the local action of eupatilin. Further pharmacokinetic studies to elucidate the local action of eupatilin are required.

• Biomolecules & Therapeutics
• /
• 제4권1호
• /
• pp.19-31
• /
• 1996

This study was performed to determine the subacute toxicities of SKI306X, an antiinflammatory herbal extract, in rats. SKI306X was administered orally to rats once a day for 4 weeks at doses of 0.3, 1.0, and 3.0 g/kg/ day. Each group consisted of 20 male and 20 female rats, including 5 male and 5 female rats per group for an interim study at the end of 2-week administration and for a 2-week recovery study, respectively. Throughout the study, all rats survived and no adverse clinical signs were observed. Although male rats treated with high dose (3.0 g/kg/day) of SKI306X showed slight loss of body weight (approximately 5%) in comparison with control animals during the administration period, their body weight loss was normally restored during the recovery period. No significant change was found in all hematological parameters of SKI306X-treated groups except for the decreased number of red blood cells in all female groups at the interim study. Statistically significant changes were observed in several blood enzyme levels of SKI306X-treated groups; however, most of these significant changes were within normal range and statistically significant values did not show dose-related responses. In SKI306X-treated groups, the absolute and relative weights of liver, heart, and stomach were statistically different from those of control group, but these differences disappeared at the end of recovery period and also drug-related gross and histopathological findings in these organs were not found. No other drug-related gross and histopathological findings were observed. It is concluded from the results of this study that non-toxic dose of SKI306X was estimated to be between 0.3 and 1.0 g/kg/day and the maximum tolerated dose of SKI306X was assumed to be higher than 3.0 g/kg/day.

• Biomolecules & Therapeutics
• /
• 제16권1호
• /
• pp.46-53
• /
• 2008

The preventive hypolipidemic effect of the aqueous extracts of Picrorrhiza Rhizoma (PR) was observed in a high fat diet (HFD) feeding hyperlipidemic mouse with their hepatoprotective effects. PR extracts (50, 100 and 200mg/kg) were orally dosed once a day for 12 weeks initiated with HFD supply, and changes on body weight and gains, liver weight, serum aspartate transferase (AST) and alanine transferase (ALT) levels were monitored with serum low density lipoprotein (LDL), high density lipoprotein (HDL), triglyceride and total cholesterol levels. The efficacy of test articles was compared to that of 10mg/kg of simvastatin (SIMVA). Dramatic decrease of both absolute and relative liver weight was dose-dependently observed in all PR extract dosing groups as compared with HFD control group. The serum AST and ALT levels were dose-dependently decreased in PR extract dosing groups. The serum LDL, triglyceride and total cholesterol levels were dose-dependently decreased in PR extract dosing groups compared to that of HFD control group. The serum HDL levels were slightly but dose-dependently increased in PR extract dosing groups as compared with control group. The efficacy on the serum lipid levels of PR extracts was slighter than that of SIMVA. Based on these results, it is concluded that water extract of PR has a relatively good favorable preventive effects on the HFD inducing hyperlipidemia and hepatopathy.

• Clinical and Experimental Reproductive Medicine
• /
• 제48권2호
• /
• pp.163-173
• /
• 2021

Objective: This study aimed to characterize a validated model for predicting oocyte retrieval in controlled ovarian stimulation (COS) and to construct model-based nomograms for assistance in clinical decision-making regarding the gonadotropin protocol and dose. Methods: This observational, retrospective, cohort study included 636 women with primary unexplained infertility and a normal menstrual cycle who were attempting assisted reproductive therapy for the first time. The enrolled women were split into an index group (n=497) for model building and a validation group (n=139). The primary outcome was absolute oocyte count. The dose-response relationship was tested using modified Poisson, negative binomial, hybrid Poisson-E_max, and linear models. The validation group was similarly analyzed, and its results were compared to that of the index group. Results: The Poisson model with the log-link function demonstrated superior predictive performance and precision (Akaike information criterion, 2,704; λ=8.27; relative standard error (λ)=2.02%). The covariate analysis included women's age (p<0.001), antral follicle count (p<0.001), basal follicle-stimulating hormone level (p<0.001), gonadotropin dose (p=0.042), and protocol type (p=0.002 and p<0.001 for short and antagonist protocols, respectively). The estimates from 500 bootstrap samples were close to those of the original model. The validation group showed model assessment metrics comparable to the index model. Based on the fitted model, a static nomogram was built to improve visualization. In addition, a dynamic electronic tool was created for convenience of use. Conclusion: Based on our validated model, nomograms were constructed to help clinicians individualize the stimulation protocol and gonadotropin doses in COS cycles.

• Clinical and Experimental Vaccine Research
• /
• 제12권2호
• /
• pp.107-115
• /
• 2023

Purpose: The present study aimed to study the immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies. Materials and Methods: This prospective cohort study of hematology patients aimed to evaluate their antibody levels against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 spike protein and seroconversion rates following two doses of the ChAdOx1 nCoV-19 vaccine. Between June and July 2021, we enrolled 61 patients and included 44 patients in our analysis. Antibody levels were assessed 8 and 4 weeks after the first and second injections, respectively, and compared with those of a healthy group. Results: Eight weeks after the first dose, the geometric mean antibody level was 1.02 binding antibody units (BAU)/mL in the patient group and 37.91 BAU/mL in the healthy volunteer group (p<0.01). Four weeks after the second dose, the geometric mean antibody level was 9.44 BAU/mL in patients and 641.6 BAU/mL in healthy volunteers (p<0.01). The seroconversion rates 8 weeks after the first dose were 27.27% and 98.86% in the patient and healthy volunteer groups, respectively (p<0.001). The seroconversion rate 4 weeks after the second dose was 47.73% in patients and 100% in healthy volunteers. Factors leading to lower seroconversion rates were rituximab therapy (p=0.002), steroid therapy (p<0.001), and ongoing chemotherapy (p=0.048). Factors that decreased antibody levels were hematologic cancer (p<0.001), ongoing chemotherapy (p=0.004), rituximab (p<0.001), steroid use (p<0.001), and absolute lymphocyte count <1,000/mm³ (p=0.009). Conclusion: Immune responses were impaired in individuals with hematologic malignancies, particularly patients undergoing ongoing therapy and B-cell-depleting therapy. Additional vaccinations should be considered for these patients, and further investigated.

• 한국의학물리학회지:의학물리
• /
• 제16권4호
• /
• pp.166-175
• /
• 2005

입체조형 동적회전조사 방사선치료(Dynamic Conformal Arc Radiotherapy, DCAR)에서 필름 선량계를 이용한 선량검증시 필름 회전중심점 이동 보정값을 최적화법으로 구하고 최적화 후 DCAR에 대한 선량 검증의 정량적 허용기준을 제시하고자 하였다. 정위방사선치료를 시행했던 7명의 전이성 뇌암 환자에서 DCAR 치료계획을 시행하고 필름 선량계로 선량을 측정하였다. 필름 선량계의 가장 큰 계통적 오차 요인인 회전중심점 이동 보정값을 최적화법으로 구하고 치료계획과 필름으로 측정된 선량분포를 비교하여 최적화 전후의 평균 선량오차와 점선량오차가 $5\%$ 이상인 지점의 비율을 얻었다. 모든 환자에서 필름 선량계의 회전중심점 이동 보정값은 1 mm 이내였다. 필름 회전중심점 이동 보정 최적화전, 후로 선량오차 결과를 산출하였다. 최적화 전, 후의 평균 선량오차의 평균은 각각 $1.70{\pm}0.36\%$, $1.34{\pm}0.20\%$이었고 점선량오차가 $5\%$ 이상인 지점 비율의 평균은 각각 $4.54{\pm}3.94\%$, $0.11{\pm}0.12\%$로서 최적화 후 선량오차가 현저히 감소하였다. 본 연구의 결과와 같이 최적화법을 이용한 필름의 회전중심점 이동값을 구하고 최적화 후의 평균 선량오차와 점선량오차가 $5\%$ 이상인 지점의 비율을 구하는 방법은 임상에서 DCAR에 대한 선량 검증 방법으로 유용하게 사용될 수 있을 것으로 기대된다.

• 한국의학물리학회지:의학물리
• /
• 제6권2호
• /
• pp.41-50
• /
• 1995

암치료용 방사선 (15 MV의 에너지를 갖는 광자선) 속에 있는 흡수선량과 불순전자 또는 산란 광자에 관한 분포를 광자선 면적 크기에 따른 변화와 광자선 면적을 반만 차폐시킨 선속에 대하여 연구 조사하였다. 광자선의 에너지를 15MV로 주어질때 광자선 최대 흡수깊이 $d^{max}$ 값은 광자선의 면적을 증가시키면 시킬수록(5$\times$5 에서 30$\times$30$\textrm{cm}^2$)d$_{max}$ 값은 감소된다. 이는 광자선 즉 방사선을 발생시키는 가속기 기계 속에 있는 여러 부품 (flattening filter, collimator jaws, tray holder,……)과 상호작용하여 형성된 불순전자로 인하여 d$_{max}$ 값이 표피쪽으로 이동되어 buildup 영역에 높은 선량흡수를 갖게 된다. 최대 흡수깊이 값을 계산할 때 이러한 현상을 고려하지 않으면 그릇된 data 값을 갖는다. 대부분의 불순 전자는 광자선 중심에 주로 분포하며 그 진행거리는 30.0mm 이하의 짧은 거리를 갖는다. 이 불순전자가 30.0mm이내(즉 buidup 영역)에 전부 흡수되므로 buidup 영역은 높은 선량흡수를 갖게되어 해를 주게된다. 그러므로 이러한 불순전자를 제거시키므로서 buidup 영역에 낮은 선량 흡수를 갖을 뿐 아니라 d$_{max}$ 값도 역시 깊은 곳까지 이동시켜 치료에 효과적인 방법 이 창출된다.